Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Aaron Mitchell, MD, MPH

Assistant Attending

Office Phone

646-888-8155

Dr. Mitchell’s research interests are in the economic determinants of cancer care delivery. His work has focused on understanding how current reimbursement models in oncology shape physician behavior and care delivery, and in particular how they may create incentives for overuse and overtreatment. He also studies how alternative reimbursement models may achieve better alignment between physician incentives and patient value, in order to improve outcomes and constrain wasteful spending. Additional research interests include drug approval and regulatory policy, drug pricing, and financial toxicity. Dr. Mitchell has a co-appointment with the Genitourinary Oncology Service, and his clinical interests are in the treatment of genitourinary malignancies, particularly prostate, bladder, and kidney cancers.

Publications


  1. 1) Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018 Jun 1;178(6):854-856. doi: 10.1001/jamainternmed.2018.0776. PubMed PMID: 29630687.

  2. 2) Mitchell AP, Basch EM, Dusetzina SB. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016 Dec 1;2(12):1628-1631. doi: 10.1001/jamaoncol.2016.2710. PubMed PMID: 27561170.

  3. 3) Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1. PubMed PMID: 26330533.

  4. 4) Mitchell A, Muluneh B, Patel R, Basch E. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. J Oncol Pharm Pract. 2017 Jan 1:1078155217719585. doi: 10.1177/1078155217719585. [Epub ahead of print] PubMed PMID: 28714357.

  5. 5) Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):e159-66. doi: 10.1016/j.clgc.2014.12.017. Epub 2014 Dec 31. PubMed PMID: 25770767.

For a complete list of publications:

https://www.ncbi.nlm.nih.gov/sites/myncbi/10WDuknTGvyks/bibliography/40395201/public/?sort=date&direction=ascending